-
Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms
•
China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider for global pharmaceutical companies, plans to jointly establish the Shanghai Biomedical Mergers and Acquisitions Equity Investment Partnership Enterprise (Limited Partnership) with Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai Junshi Biosciences Co., Ltd., and MediTrust Health, among…
-
Shanghai Pharmaceuticals’ MediTrust Health Partners with Eisai for Comprehensive Patient Services
•
Shanghai Pharmaceuticals Holding Co., Ltd’s (HKG: 2607, SHA: 601607) subsidiary, MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a strategic partnership with Japanese pharmaceutical company Eisai (TYO: 4523). This collaboration grants Eisai access to MediTrust Health’s “One-Code Direct Payment-Diversified Payment Platform,” aiming to establish…
-
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
•
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced a strategic partnership with MediTrust Health, an insurance, financing, and direct-to-patient pharmacy subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. This collaboration will focus on integrating Grand Pharma’s 90Y product into various commercial insurance schemes, aiming…
-
Shanghai Pharmaceuticals’ MediTrust Health Partners with Yuanda Shuyang on Rare Disease Treatment Model
•
Shanghai Pharmaceuticals Holding Co., Ltd’s (SHA: 601607, HKG: 2607) subsidiary, MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a partnership with Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. The collaboration aims to strengthen the development of a “Chinese model” for the diagnosis and treatment of…
-
MediTrust Health Secures Series C+ Funding with HSBC as Strategic Investor
•
MediTrust Health, the insurance, financing, and direct-to-patient pharmacy subsidiary of China-based Shanghai Pharmaceuticals Holding Co., Ltd, has raised an undisclosed amount in a Series C+ financing round. HSBC joined as a strategic investor, alongside other strategic shareholders including SPH, China Life Reinsurance Co., Ltd, and Shanghai Healthcare Capital (SHC). Focus…
